Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26606547 | 1.00 | EGFR (0.43) | EGFRCYP2D6HSD11B1PRMT5CYP3A4 | |
| SCHEMBL25406382 | 0.88 | EGFR (0.47) | EGFRCYP2D6HSD11B1CYP3A4CYP2C9 | |
| SCHEMBL25406377 | 0.88 | EGFR (0.47) | EGFRCYP2D6HSD11B1CYP3A4CYP2C9 | |
| SCHEMBL16767773 | 0.85 | HSD11B1 (0.46) | EGFRCYP2D6HSD11B1PRMT5HPGD | |
| SCHEMBL16767775 | 0.85 | HSD11B1 (0.46) | EGFRCYP2D6HSD11B1PRMT5HPGD | |
| SCHEMBL29531255 | 0.85 | HSD11B1 (0.46) | EGFRCYP2D6HSD11B1PRMT5HPGD | |
| SCHEMBL23408954 | 0.82 | PRMT5 (0.50) | EGFRCYP2D6HSD11B1PRMT5HCAR1 | |
| SCHEMBL24457938 | 0.82 | PRMT5 (0.44) | EGFRCYP2D6HSD11B1PRMT5HRH3 | |
| SCHEMBL24457922 | 0.82 | PRMT5 (0.50) | EGFRCYP2D6HSD11B1PRMT5HCAR1 | |
| SCHEMBL24457962 | 0.82 | PRMT5 (0.50) | EGFRCYP2D6HSD11B1PRMT5HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339922-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023070114-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339922-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885CYP2D6 4065/4885HSD11B1 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.